Your Gut Bacteria Inject Proteins Directly Into Your Cells

The Improving Gut Health Team • 2026-04-03 • updated Sat Oct 31 • 7 min read
Editorial byline — how this site is written · educational content, not medical advice

Scientists discover gut bacteria use syringe-like structures to inject proteins into human cells, actively controlling immune responses. This finding rewrites our understanding of the microbiome.

Your gut bacteria inject proteins directly into your cells

This article is for educational purposes only and is not medical advice. Digestive symptoms and immune conditions can have many causes. Always consult a qualified clinician before changing your diet, supplements, or treatment plan.

Quick answer

Many common gut bacteria carry microscopic, syringe-like structures called type III secretion systems (T3SS) that inject bacterial proteins directly into human cells. A 2026 study in Nature Microbiology found that roughly 80% of Pseudomonadota bacteria sampled from healthy human guts carry intact T3SS machinery, and that the proteins these commensal bacteria deliver can enter human cells and alter immune signaling — specifically NF-κB signaling and cytokine secretion — in laboratory experiments. The same study found genes for these injected proteins are enriched in the gut microbiomes of people with Crohn's disease. This reframes gut bacteria as active participants in your biology rather than passive residents, and it may partly explain how microbiome changes contribute to inflammatory and autoimmune conditions.

The discovery

For years, researchers knew the gut microbiome influenced immune and metabolic health, but the mechanisms remained blurry. Most evidence was correlational — people with certain diseases had different gut bacteria — without explaining how those bacteria affected human biology.

A large international collaboration led by Professor Pascal Falter-Braun at Helmholtz Munich, together with partners in Marseille, Utrecht, Aachen, Vienna, Boston, and Liège, published a study in Nature Microbiology (online January 26, 2026) that supplies a direct mechanism: many commensal gut bacteria use type III secretion systems to inject their own proteins into human cells. The work was co-led by first authors Young and Dohai and built an experimentally mapped network of interactions between human proteins and the effector proteins that commensal bacteria deliver.

Until recently, this machinery was thought to belong mainly to pathogens like Salmonella, which use it to hijack host cells during infection. The new finding shows that bacteria we carry in a healthy gut — not just disease-causing invaders — possess and presumably use the same injection systems.

What are type III secretion systems?

Type III secretion systems are molecular syringes: multi-protein structures that span the bacterial cell envelope and pierce a host cell's membrane, allowing the bacterium to push effector proteins directly into the cell's interior. Once inside, these effectors can modify signaling pathways, immune responses, and cell behavior.

The research team analyzed the genomes of gut bacteria from healthy people and found that about 80% of Pseudomonadota — a major group of commensal gut bacteria that includes E. coli and many other resident species — carry intact T3SS gene clusters. Machine-learning screening predicted candidate effector proteins, and a striking pattern emerged: the predicted commensal effectors have sequence and structural features that are measurably distinct from the effectors pathogens use. Commensal bacteria appear to have evolved their own dialect of this injection language, likely tuned for long-term cohabitation rather than acute attack.

What the study actually found

The findings are notable because they move beyond prediction to measurement:

  • A physical interaction map. The team experimentally constructed a meta-interactome — a systematic map of which human proteins are contacted by which commensal effector proteins. This is the first systems-level view of how injected bacterial proteins could physically touch human cell machinery.
  • Disease-relevant targets. Network analysis showed that the human protein neighborhoods targeted by these effectors are enriched for genetic variants previously linked to microbiome-associated conditions, including autoimmune and metabolic diseases. In other words, the proteins your gut bacteria inject tend to land near genes where variation already influences immune and metabolic health.
  • Functional confirmation. In laboratory experiments, commensal effectors were translocated into human cells and modulated NF-κB signaling — a master switch of inflammation — and changed cytokine secretion, the chemical messaging system immune cells use to coordinate responses. Dysregulated NF-κB and cytokine signaling are central to chronic intestinal inflammation.
  • A Crohn's–colitis split. Metagenomic analysis of patient cohorts found genes encoding these effectors were enriched in Crohn's disease but depleted in ulcerative colitis — two forms of inflammatory bowel disease that are often lumped together. The bacteria carrying the machinery also differed between the two conditions.

The Crohn's disease connection

The enrichment of effector genes in Crohn's disease is the most clinically provocative result. It suggests that direct protein transfer from bacteria to human cells may contribute to the chronic inflammation that defines Crohn's, and it offers a mechanistic bridge between two observations that never quite fit together: that Crohn's patients have altered microbiomes, and that immune signaling in their intestines is chronically overactivated.

This fits with a broader research shift toward strain-level and mechanism-level explanations in IBD. E. coli strains associated with Crohn's, for example, carry distinct virulence- and persistence-associated traits compared with commensal strains — the same species can behave as symbiont or pathobiont depending on its gene content. Microbiome research in Crohn's is also moving toward therapeutic targeting, including in intestinal fibrosis, where microbial drivers are being mapped to intervention points.

An important caveat: enrichment in Crohn's microbiomes does not prove causation. Inflamed intestines change which bacteria thrive, so effector enrichment could be a consequence of the disease environment as well as a contributor to it. Follow-up work in models and longitudinal cohorts will be needed to separate driver from passenger.

Injection systems beyond type III

T3SS is not the only delivery route. Bacteria also deploy type VI secretion systems (T6SS), spring-loaded spear-like devices used mainly in battles between bacteria, and research increasingly shows some of their toxins can cross into host cells too. A 2025 Cell Reports study characterized a T6SS-delivered RNase effector that kills both bacterial competitors and host cells, demonstrating that "trans-kingdom" attacks — bacterial weapons that act on human cells — are a real and evolving theme. The gut, in other words, is not just a chemical conversation; it includes direct hardware-level contact between bacterial and human cells.

Why this matters for you

  1. Gut bacteria actively manipulate your cells. They are not passive passengers; they carry and likely use machinery that injects proteins into human cells, shaping immune signaling from the inside.
  2. Strains matter more than species. Whether a bacterium carries particular effector genes may matter more than its Latin name — one more reason "take a probiotic" is too coarse to predict outcomes, and why strain-level evidence is emphasized across this site's probiotic coverage.
  3. Autoimmune connections sharpen. The overlap between effector-targeted human proteins and autoimmune- and metabolic-disease genes gives researchers a concrete map to hunt for mechanisms — and eventually, perhaps, biomarkers.
  4. Testing may evolve. Sequencing that reports which effector genes your microbiome carries could eventually complement standard comprehensive stool testing, moving from "which bacteria are present" to "what are they doing to your cells."
  5. Diversity keeps its starring role. A microbiome dominated by a narrow set of effector-heavy strains presents a different signaling profile than a diverse one — a mechanistic angle on why microbiome diversity tracks with health outcomes.

What comes next

Future research will map how specific effector proteins behave in different tissues and disease settings, and test whether injection is constant, conditional, or context-dependent in the living gut. Scientists also want to know whether these systems first evolved to support peaceful coexistence with humans and were later co-opted by pathogens, or the other way around. The implications extend beyond Crohn's disease: because effectors touch fundamental immune signaling, the same mechanism may play roles in metabolic disorders and other autoimmune conditions.

Key takeaways

  • About 80% of Pseudomonadota bacteria from healthy human guts carry intact type III secretion systems — injection machinery once thought to belong to pathogens.
  • Commensal effector proteins are structurally distinct from pathogen ones and can enter human cells, modulating NF-κB signaling and cytokine secretion in lab experiments.
  • Effector genes are enriched in Crohn's disease but depleted in ulcerative colitis — an association, not yet proof of causation.
  • Effector-targeted human proteins sit in gene neighborhoods already linked to autoimmune and metabolic disease risk.
  • This is basic science today: no test, probiotic, or treatment based on effector profiles exists for clinical use yet.

FAQ

Does this discovery mean I should change my probiotic or diet?

No. The study was conducted on bacterial genomes, protein interaction maps, and cells in the laboratory — not in patients taking interventions. Nothing about it changes current, evidence-based guidance for probiotics or diet. Its value is a new map for future research into how gut bacteria mechanically influence immune health.


This article is for educational purposes only and is not medical advice. It describes basic-science research and does not support any diagnostic test, supplement, or treatment decision on its own. If you have symptoms or a diagnosed condition such as Crohn's disease or ulcerative colitis, work with a qualified gastroenterologist before making changes.

References

  • Young, V., Dohai, B., Halder, H., et al., Falter-Braun, P. (2026). Effector-host interactome map links type III secretion systems in healthy gut microbiomes to immune modulation. Nature Microbiology 11(2):442–460. PMID 41588163.
  • Nandi, I., Aroeti, B. (2023). MAPKs and enteric bacterial pathogens: a complex interplay. Int J Mol Sci 24(15):11905. PMID 37569283.
  • Aceto, G. M., et al. (2026). Deciphering the implications of Escherichia coli in inflammatory bowel disease: from symbiont to pathogen. Pathogens 15(5):548. PMID 42198674.
  • Kim, J. H., et al. (2026). Gut microbiome: a key driver and therapeutic target of intestinal fibrosis in Crohn's disease. Intest Res. PMID 42575494.
  • Wang, Y., et al. (2025). A trans-kingdom T6SS RNase effector targeting both prokaryotic and host cells for pathogenesis. Cell Reports 44(8):116074. PMID 40720240.
  • Turnbaugh, P. J., et al. (2006). The Human Microbiome Project. Nature 449:804–810. DOI 10.1038/nature06244.

Citations

  1. Young V, Dohai B, et al. Effector-host interactome map links type III secretion systems in healthy gut microbiomes to immune modulation. Nature Microbiology 2026 — DOI: 10.1038/s41564-025-02241-y
  2. Nandi I, Aroeti B. MAPKs and enteric bacterial pathogens: a complex interplay. Int J Mol Sci 2023 — DOI: 10.3390/ijms241511905
  3. Aceto GM, et al. Deciphering the implications of Escherichia coli in inflammatory bowel disease: from symbiont to pathogen. Pathogens 2026 — DOI: 10.3390/pathogens15050548
  4. Kim JH, et al. Gut microbiome: a key driver and therapeutic target of intestinal fibrosis in Crohn's disease. Intest Res 2026 — DOI: 10.5217/ir.2026.00013
  5. Wang Y, et al. A trans-kingdom T6SS RNase effector targeting both prokaryotic and host cells for pathogenesis. Cell Rep 2025 — DOI: 10.1016/j.celrep.2025.116074
  6. Turnbaugh PJ et al. The Human Microbiome Project — DOI: 10.1038/nature06244